Zura Bio Limited (NASDAQ:ZURA) Insider Michael Howell Acquires 7,987 Shares of Stock

Zura Bio Limited (NASDAQ:ZURA) insider Michael Howell bought 7,987 shares of the stock in a transaction dated Monday, April 22nd. The shares were purchased at an average price of $3.13 per share, for a total transaction of $24,999.31. Following the purchase, the insider now owns 7,987 shares of the company’s stock, valued at approximately $24,999.31. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Zura Bio Stock Performance

Shares of NASDAQ:ZURA opened at $3.31 on Thursday. Zura Bio Limited has a 12-month low of $2.00 and a 12-month high of $14.00. The company’s 50 day moving average price is $3.21 and its two-hundred day moving average price is $4.04.

Institutional Investors Weigh In On Zura Bio

Several institutional investors have recently made changes to their positions in the stock. Armistice Capital LLC raised its holdings in Zura Bio by 66.3% in the 3rd quarter. Armistice Capital LLC now owns 1,580,000 shares of the company’s stock valued at $10,428,000 after acquiring an additional 630,000 shares in the last quarter. Silverarc Capital Management LLC increased its position in shares of Zura Bio by 152.5% in the third quarter. Silverarc Capital Management LLC now owns 404,040 shares of the company’s stock worth $2,667,000 after purchasing an additional 244,040 shares during the period. Eisler Capital US LLC acquired a new position in Zura Bio in the third quarter valued at about $660,000. Bank of New York Mellon Corp bought a new stake in Zura Bio during the third quarter worth about $224,000. Finally, Forefront Analytics LLC acquired a new stake in Zura Bio during the third quarter worth about $95,000. 61.14% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Oppenheimer reaffirmed an “outperform” rating and issued a $16.00 price objective (down from $17.00) on shares of Zura Bio in a report on Monday, April 1st. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $16.40.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.